blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2405940

EP2405940 - ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.06.2022
Database last updated on 15.07.2024
FormerThe patent has been granted
Status updated on  02.07.2021
FormerGrant of patent is intended
Status updated on  09.03.2021
FormerExamination is in progress
Status updated on  02.11.2016
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Secretary of State for Health and Social Care
Ministerial Correspondence and Public Enquiries
Department of Health and Social Care
39 Victoria Street
London SW1H 0EU / GB
For all designated states
Micropharm Limited
Station Road Industrial Estate
Newcastle Emlyn, Carmarthenshire SA38 9BY / GB
[2021/31]
Former [2021/11]For all designated states
Secretary of State for Health and Social Care
Ministerial Correspondence and Public Enquiries
Department of Health and Social Care
39 Victoria Street
London SW1H 0EU / GB
For all designated states
Micropharm Limited
Station Road Industrial Estate
Newcastle Emlyn, Carmarthenshire SA38 9BX / GB
Former [2020/19]For all designated states
Secretary of State for Health and Social Care
Ministerial Correspondence and Public Enquiries
Department of Health and Social Care
39 Victoria Street
London SW1H 0EU / GB
For all designated states
Micropharm Limited
Station Road Industrial Estate Newcastle
Emlyn SA38 9BX / GB
Former [2013/26]For all designated states
The Secretary of State for Health
Richmond House
79 Whitehall
London SW1A 2NS / GB
For all designated states
Micropharm Limited
Station Road Industrial Estate Newcastle
Emlyn SA38 9BX / GB
Former [2012/03]For all designated states
Health Protection Agency
Porton Down Salisbury
Wiltshire SP4 0JG / GB
For all designated states
Micropharm Limited
Station Road Industrial Estate Newcastle
Emlyn SA38 9BX / GB
Inventor(s)01 / SHONE, Clifford
UK Health Security Agency
Porton Down
Salisbury Wiltshire SP4 0JG / GB
02 / LANDON, John
MicroPharm Limited
Station Road Industrial Estate
Newcastle Emlyn Carmarthenshire SA38 9BY / GB
 [2021/31]
Former [2012/03]01 / SHONE, Clifford
Health Protection Agency
Porton Down
Salisbury Wiltshire SP4 0JG / GB
02 / LANDON, John
MicroPharm Limited
Station Road Industrial Estate
Newcastle Emlyn Carmarthenshire SA38 9BX / GB
Representative(s)Titmus, Craig Edward
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[2021/31]
Former [2012/03]MacLean, Martin Robert
Mathys & Squire LLP 120 Holborn London
EC1N 2SQ / GB
Application number, filing date10706731.619.02.2010
[2021/31]
WO2010GB50288
Priority number, dateGB2009000285120.02.2009         Original published format: GB 0902851
GB2009001615315.09.2009         Original published format: GB 0916153
[2012/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010094970
Date:26.08.2010
Language:EN
[2010/34]
Type: A1 Application with search report 
No.:EP2405940
Date:18.01.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 26.08.2010 takes the place of the publication of the European patent application.
[2012/03]
Type: B1 Patent specification 
No.:EP2405940
Date:04.08.2021
Language:EN
[2021/31]
Search report(s)International search report - published on:EP26.08.2010
ClassificationIPC:C07K16/12, A61K39/00, A61P31/04
[2021/08]
CPC:
C07K16/1282 (EP,US); A61P31/04 (EP); A61K2039/505 (EP,US);
C07K2317/20 (EP,US)
Former IPC [2012/03]A61K39/40, C07K16/12
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/03]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:ANTIKÖRPER GEGEN CLOSTRIDIUM DIFFICILE TOXINE[2012/03]
English:ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS[2012/03]
French:ANTICORPS CONTRE LES TOXINES DE CLOSTRIDIUM DIFFICILE[2012/03]
Entry into regional phase19.09.2011National basic fee paid 
19.09.2011Designation fee(s) paid 
19.09.2011Examination fee paid 
Examination procedure17.12.2010Request for preliminary examination filed
International Preliminary Examining Authority: EP
19.09.2011Amendment by applicant (claims and/or description)
19.09.2011Examination requested  [2012/03]
05.02.2015Despatch of a communication from the examining division (Time limit: M06)
05.08.2015Reply to a communication from the examining division
28.04.2016Despatch of a communication from the examining division (Time limit: M06)
28.10.2016Reply to a communication from the examining division
14.09.2017Cancellation of oral proceeding that was planned for 25.09.2017
25.09.2017Date of oral proceedings (cancelled)
21.11.2017Despatch of a communication from the examining division (Time limit: M02)
27.11.2017Reply to a communication from the examining division
19.04.2018Despatch of a communication from the examining division (Time limit: M06)
05.10.2018Reply to a communication from the examining division
16.04.2020Cancellation of oral proceeding that was planned for 23.04.2020
23.04.2020Date of oral proceedings (cancelled)
20.01.2021Date of oral proceedings
17.02.2021Minutes of oral proceedings despatched
10.03.2021Communication of intention to grant the patent
24.06.2021Fee for grant paid
24.06.2021Fee for publishing/printing paid
24.06.2021Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.02.2015
Opposition(s)06.05.2022No opposition filed within time limit [2022/28]
Fees paidRenewal fee
29.02.2012Renewal fee patent year 03
26.02.2013Renewal fee patent year 04
28.02.2014Renewal fee patent year 05
27.02.2015Renewal fee patent year 06
25.02.2016Renewal fee patent year 07
27.02.2017Renewal fee patent year 08
26.02.2018Renewal fee patent year 09
26.02.2019Renewal fee patent year 10
24.02.2020Renewal fee patent year 11
25.02.2021Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.02.2010
AT04.08.2021
CY04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
MK04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
TR04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU19.02.2022
BE28.02.2022
[2024/29]
Former [2024/22]HU19.02.2010
AT04.08.2021
CY04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
MK04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU19.02.2022
BE28.02.2022
Former [2024/20]HU19.02.2010
AT04.08.2021
CY04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU19.02.2022
BE28.02.2022
Former [2024/18]HU19.02.2010
AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU19.02.2022
BE28.02.2022
Former [2023/10]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU19.02.2022
BE28.02.2022
Former [2022/47]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
LU19.02.2022
Former [2022/44]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
MC04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/36]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
IT04.08.2021
LT04.08.2021
LV04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SI04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/26]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SK04.08.2021
SM04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/24]AT04.08.2021
CZ04.08.2021
DK04.08.2021
EE04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
PL04.08.2021
RO04.08.2021
SE04.08.2021
SK04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/21]AT04.08.2021
DK04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
PL04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/11]AT04.08.2021
ES04.08.2021
FI04.08.2021
HR04.08.2021
LT04.08.2021
LV04.08.2021
PL04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
GR05.11.2021
IS04.12.2021
PT06.12.2021
Former [2022/09]AT04.08.2021
ES04.08.2021
FI04.08.2021
LT04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
PT06.12.2021
Former [2022/08]AT04.08.2021
ES04.08.2021
FI04.08.2021
LT04.08.2021
SE04.08.2021
BG04.11.2021
NO04.11.2021
Former [2022/07]AT04.08.2021
LT04.08.2021
NO04.11.2021
Cited inInternational search[Y]WO2006121422  (UNIV MASSACHUSETTS [US], et al) [Y] 1-13 * the whole document *;
 [Y]WO9920304  (ORAVAX INC [US]) [Y] 1-13 * the whole document *;
 [Y]WO2006071877  (DIVERSA CORP [US], et al) [Y] 1-13 * the whole document *;
 [Y]  - KINK J A ET AL, "ANTIBODIES TO RECOMBINANT CLOSTRIDIUM DIFFICILE TOXINS A AND B ARE EFFECTIVE TREATMENT AND PREVENT RELAPSE OF C. DIFFICILE-ASSOCIATED DISEASE IN A HAMSTER MODEL OF INFECTION", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, (19980501), vol. 66, no. 5, ISSN 0019-9567, pages 2018 - 2025, XP002912254 [Y] 1-13 * the whole document *
 [A]  - YOUNG ET AL, "The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile", REGULATORY TOXICOLOGY AND PHARMACOLOGY, ACADEMIC PRESS,NEW YORK, NY, US LNKD- DOI:10.1016/J.YRTPH.2006.12.001, (20070315), vol. 47, no. 3, ISSN 0273-2300, pages 317 - 326, XP005921864 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.yrtph.2006.12.001
 [A]  - ASLAM ET AL, "Treatment of Clostridium difficile-associated disease: old therapies and new strategies", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US LNKD- DOI:10.1016/S1473-3099(05)70215-2, (20050901), vol. 5, no. 9, ISSN 1473-3099, pages 549 - 557, XP005040964 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1473-3099(05)70215-2
 [A]  - TAYLOR C P ET AL, "Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/J.VACCINE.2008.04.042, vol. 26, no. 27-28, ISSN 0264-410X, (20080625), pages 3404 - 3409, (20080507), XP022710544 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2008.04.042
 [A]  - STUART MCPHERSON ET AL, "Intravenous Immunoglobulin for the Treatment of Severe, Refractory, and Recurrent Clostridium difficile Diarrhea", DISEASES OF THE COLON & RECTUM, SPRINGER-VERLAG, NE LNKD- DOI:10.1007/S10350-006-0511-8, (20060315), vol. 49, no. 5, ISSN 1530-0358, pages 640 - 645, XP019388873 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1007/s10350-006-0511-8
Examination   - RICHARD C. DART ET AL, "Efficacy, safety, and use of snake antivenoms in the United States", ANNALS OF EMERGENCY MEDICINE, (20010201), vol. 37, no. 2, doi:10.1067/mem.2001.113372, ISSN 0196-0644, pages 181 - 188, XP055165220

DOI:   http://dx.doi.org/10.1067/mem.2001.113372
    - A. ROBERTS ET AL, "DEVELOPMENT AND EVALUATION OF AN OVINE ANTIBODY-BASED PLATFORM FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION", INFECTION AND IMMUNITY, (20120201), vol. 80, no. 2, doi:10.1128/IAI.05684-11, ISSN 0019-9567, pages 875 - 882, XP055059618

DOI:   http://dx.doi.org/10.1128/IAI.05684-11
    - ANTHONY F. PIZON ET AL, "Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations", ACADEMIC EMERGENCY MEDICINE, US, (20070401), vol. 14, no. 4, doi:10.1197/j.aem.2006.10.095, ISSN 1069-6563, pages 373 - 376, XP055343366

DOI:   http://dx.doi.org/10.1197/j.aem.2006.10.095
    - TAMMI H SCHAEFFER ET AL, "Treatment of Chronically Digoxin-Poisoned Patients With a Newer Digoxin Immune Fab-A Retrospective Study", J AM OSTEOPATH ASSOC, (20101001), vol. 110, no. 10, pages 587 - 592, XP055343373
by applicant   - SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 484
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NAT'!. ACAD. SCI. USA, (1988), vol. 85, page 2444
    - ALTSCHUL, J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - CHOTHIA, C. ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - HUSTON ET AL., PROC. NATL. ACAD. SCL USA, (1988), vol. 85, pages 5879 - 5883
    - ROBERTS; SHONE, TOXICON, (2001), vol. 39, pages 325 - 333
    - RUPNIK ET AL., J. CLINICAL MICROBIOL., (1998), vol. 36, pages 2240 - 2247
    - RUPNIK ET AL., MICROBIOLOGY, (2001), vol. 147, pages 439 - 447
    - pET vector Expression System Manual, MERCK KGAA
    - LIA M ET AL., PROTEIN EXPRESSION & PURIFICATION, (2004), vol. 33, pages 1 - 10
    - YANG G; ZHOU B; WANG J; HE X; SUN X; NIE W; TZIPORI S; FENG H, "Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium", BMC MICROBIOL., (2008), vol. 8, page 192
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.